Compare RCAT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | PCRX |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.4M | 1.0B |
| IPO Year | 2017 | 2011 |
| Metric | RCAT | PCRX |
|---|---|---|
| Price | $7.41 | $26.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $12.50 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 6.9M | 723.2K |
| Earning Date | 12-16-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $7,443,942.00 | ★ $716,791,000.00 |
| Revenue This Year | $396.50 | $6.24 |
| Revenue Next Year | $296.06 | $9.53 |
| P/E Ratio | ★ N/A | $55.78 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $4.58 | $18.17 |
| 52 Week High | $16.70 | $27.64 |
| Indicator | RCAT | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 67.86 |
| Support Level | $8.01 | $25.17 |
| Resistance Level | $8.80 | $24.81 |
| Average True Range (ATR) | 0.60 | 0.96 |
| MACD | 0.14 | 0.26 |
| Stochastic Oscillator | 31.72 | 76.49 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.